Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies Acquires BAC BV

Published: Tuesday, January 22, 2013
Last Updated: Tuesday, January 22, 2013
Bookmark and Share
The acquisition expands Life Technologies capabilities and product offerings in biopharmaceutical research and manufacturing.

Life Technologies Corporation  announces its acquisition of BAC BV, a privately held company based in the Netherlands, and a leader in the discovery, development and manufacture of protein purification products. 

"Our acquisition of BAC BV positions Life Technologies as a leading provider of end-to-end solutions that are widely utilized in the bioprocess workflow," said Tony Hunt, head of BioProduction at Life Technologies. "Combining BAC's current portfolio and pipeline with our pre-existing portfolio expands Life's product offering and enables us to compete more fully across the protein purification market. We intend to immediately integrate the portfolios and leverage the Life commercial platform to drive accelerated growth in this market."

Bioprocessing is the production and analytical testing of biologically-based therapeutics, which are developed in cultured cells or microorganisms, and include drugs, vaccines, biosimilars, and gene and cell therapies. Life Technologies' Gibco® brand is the market leader in cell culture media, a position it has held for 50 years, and the company more recently integrated its POROS® brand of chromatography resins for purification of therapeutic products into the Bioproduction portfolio.

The acquisition expands Life's existing portfolio by adding BAC BV's unique set of innovative and proprietary affinity ligands to the company's world-class POROS® resins. Affinity ligands are molecules capable of binding with very high affinity to specific proteins, and are typically attached to chromatography resins in a production-scale, bio-purification process.

Life customers will benefit from a streamlined approach to protein purification with tailored end-to-end solutions. In addition to Gibco® culture media, POROS® resins and the BAC BV affinity ligand portfolio for protein purification, Life also offers the Applied Biosystems® SEQ rapid molecular kits for contaminant and impurity testing of bio-therapeutic products.  

"We are looking forward to developing and providing unique, enabling products from our combined portfolios and capabilities to our purification customers," said Laurens Sierkstra, Ph.D., chief executive officer of BAC BV. Sierkstra and an additional 34 employees will join Life Technologies.Current BAC BV facilities, a manufacturing site in Naarden and R&D facility in Leiden, Netherlands, will remain in operation. 

Financial terms of the deal were not disclosed. The tuck-in acquisition of BAC BV is expected to be neutral to the company's overall ROIC three years after close.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Life Technologies to Accelerate Development of Ion Torrent Semiconductor Technology
Company to accelerate technology for a broad set of proteomic and antibody-based applications after passing internal Life Technologies R&D milestones.
Thursday, July 12, 2012
Scientific News
Protein-Based “Cancer Signature” Uncovered
Researchers investigated the expression of ribosomal proteins in human tissues and discovered a cancer type specific signature which could be used to predict the progression of the disease.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
‘NoBody,’ a Microprotein On a Mission
Researchers identify over 400 microproteins encoded in the human genome, one of which clears unneeded genetic material inside cells.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Largest Resource of Protein-Protein Interactions
Researchers have developed the largest ever database of protein-protein interactions.
Bright Red Fluorescent Protein Created
Scientists have created a bright red, fluorescent protein that could be used to track essential cellular processes.
Protein Self-Regulates Abundance
Researchers have uncovered how a protein, that plays a crucial role in embryonic stem cell renewal, is regulated.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Building Better Nanodiscs
Researchers have improved upon the design of nanodiscs that provide an unprecedented view of viral infection.
Breast Cancer Cells Starve for Cystine
Depriving triple negative breast cancer, a treatment-resistant form of breast cancer, of cystine results in cancer cell death.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!